Vamifeport not checked

CSL Behring · Vifor (International) Inc. · CSL624 · VIT-2763

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
6 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis
Main trialPhase 2
“This is a phase 2, multicenter, randomized, placebo-controlled, double-blind, parallel-group, proof-of-concept study to assess vamifeport in adult participants with homeostatic iron regulator gene-related hereditary hemochromatosis (HFE-HH). The primary objective of the study is to assess the effect of vamifeport treatment on magnetic resonance imaging (MRI)-based liver iron concentration (LIC) in adult participants with HFE-HH.”In the company’s words, NCT07332091 on ClinicalTrials.gov
Other names
CSL624 · VIT-2763

Other drugs for Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis

All 2 drugs for Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials6

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 15 Apr 2028 Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
Phase 2Completed 11 Oct 2021 Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Efficacy of VIT-2763 in β-thalassaemia
Phase 2Withdrawn Jul 2023 Efficacy and Safety Study of Multiple Doses of VIT-2763 in Adults With Transfusion-dependent Beta-thalassemia
Phase 2Completed 7 Mar 2024 Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell Disease
Phase 1Completed 29 Dec 2021 Bioavailability Study Comparing 2 Vamifeport Oral Formulations in Fasted Versus Fed State in Healthy Subjects
Phase 1Completed 1 Jul 2025 Effect of Food on the Oral Bioavailability of a Prolonged-release Formulation of Vamifeport in Healthy Adults
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Vamifeport

Following is part of Solo: you see every change to Vamifeport the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in